as per annexure enclosed
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals reported strong full-year FY2026 results with consolidated revenue of Rs. 252,285 million (up 15.7% YoY) and consolidated PAT of Rs. 20,027 million (up 33% YoY). Standalone PAT stood at Rs. 14,926 million (up 15.1% YoY). The Board approved a final dividend of Rs. 10 per share (200%), with record date August 14, 2026 and AGM on August 25, 2026. Key corporate actions include a merger of wholly-owned subsidiary Apollo Hospitals North Ltd into the company, and a transaction where subsidiary AHLL will divest Apollo Specialty Hospitals and Apollo Fertility Centre to Kids Clinic India Limited (Cloudnine) for Rs. 15,500 million (cash + equity). A separate composite scheme for demerger and listing of the pharmacy distribution and digital health business (Apollo Healthtech) is also in progress. Auditors issued an unmodified opinion. Exceptional item of Rs. 192 million was recorded due to labour code changes.
Strong 33% PAT growth and 170bps EBITDA margin expansion signal healthy operational performance. The proposed demerger and Cloudnine transaction represent significant structural changes that could unlock value for shareholders in the medium term.